Celemics launches the CRV Panel, which can quickly and accurately identify several types of viruses including mutations of the Covid-19 virus
SINGAPORE, January 6, 2021 /EINPresswire.com/ — South Korean biomaterial company Celemics Inc. has launched an all-in-one test kit that can potentially save many lives. Named the Comprehensive Respiratory Virus (CRV) Panel, the test kit is able to identify and sequence nine respiratory virus types and 39 strains, including various new mutations of the Covid-19 influenza.
The CRV Panel is able to yield affirmative results even if a clinical specimen is of low quality, and can also test for double pandemic and co-infection possibilities.
Virus identification and diagnosis within a day
The CRV Panel just might be the reprieve that healthcare resources around the world – most stretched to their limits by the ongoing battle with Covid-19 – have been searching for.
Turnaround of results can be as short as one day, as opposed to regular swab testing which requires 3-5 days to yield results. Aside from minimising quarantine durations, such a breakthrough also enables the swift administration of appropriate treatments for respiratory symptoms similar to Covid-19, thereby reducing potential fatalities.
“There are many types of viruses that infect their host through the respiratory tract. While their species may differ, their symptoms, which include fever and coughing, tend to be similar. As treatment will differ depending on the strain, it is important to discover the specific virus a patient is infected with to correctly cure them,” elaborates Celemics Inc’s CEO, Kim Hyoki, who is keen to introduce the CRV Panel to research and medical facilities around the world.
“Due to the recent COVID-19 pandemic, respiratory viral diseases are becoming a more dire global health and social issue. As a positive coronavirus test forces the patient to be quarantined for the duration of their treatment, there is a heavy toll on the individual. It is also predicted that winter and colder weather will raise the rate of infection from other respiratory viruses such as the seasonal flu, necessitating the development of technology that can accurately analyse multiple viral strains at once.
“If multiple respiratory viruses can be analysed at once, it can save time and money compared to checking one virus at a time to determine which virus they are infected with, and at the same time, it can be analysed accurately even if they are infected with multiple viruses. It differentiates itself from other products already released into the market through its ability to analyse viruses accurately using NGS technology. Compared to RT-PCR (Reverse Transcription Polymerase Chain Reaction), the current standard for virus analysis, the CRV Panel is also able to accurately obtain the whole genomic sequences for several viral strains at once. It can be used in testing methodology development, vaccine discovery and infection contact tracing.”
Mr Kim also elaborated on how his company’s CRV Panel will also help fight mutations of Covid-19. Designed to identify, detect and sequence each pathogen and any present mutations in a single reaction, it reveals information on the epidemiology and pathogenesis of viruses.
“As several mutations of COVID-19 are occurring around the world, the usage of RT-PCR technology, to test for COVID-19 infection possibilities would lead to high rates of false negative results when new mutations are detected, and would put immense pressure on kit providers to constantly improve on their current testing methodology and renew their experimental licenses. Our CRV Panel can overcome these limitations.”
The CRV Panel is available in the United States, Europe, Latin America, Middle East, Singapore, Malaysia, and Thailand via Celemics’ certified retailers.
About Celemics Inc.
Celemics is a biomaterial technology company that creates innovations in DNA-based materials with its novel sequencing technologies to disrupt the paradigm of a range of industries including pharmaceutical, microbiome, synthetic biology, and agriculture biotechnology. Established in 2010, Celemics has developed its proprietary MSSIC™ (Massively Separated and Sequence Identified Cloning), a microwell chip and laser technology that automates cloning and sequencing processes. Leveraging this innovative and unparalleled technology, Celemics has manufactured a broad range of next-generation sequencing (NGS) products including target enrichment panels, NGS library preparation tools, and reagents, which are recognized for its industry-leading quality and cost by customers around the globe. All of Celemics’ facilities are ISO9001/ISO13485/GMP certified. Celemics has its headquarter in Seoul, Korea, and has a regional office in Beijing, China. For more information about Celemics, please visit www.celemics.com.
Source: EIN Presswire